Description of Research: Krishna Rao
Dr. Rao’s clinical and research interests include the diagnosis and management of healthcare-associated infections, especially Clostridium difficile infection. His clinical work includes managing the University of Michigan Fecal Microbiota Transplantation (stool transplant) program for recurrent Clostridium difficile infection, which he co-founded. He works with the Antimicrobial Subcommittee of the Pharmacy and Therapeutics Committee, where he provides expertise and support in the use of procalcitonin, a novel and promising biomarker for bacterial infections. He research includes infections in older adults and is supported by the Claude D. Pepper Older Americans Independence Center of the University of Michigan Institute of Gerontology.
His research is primarily conducted through the Enterics Research Investigative Network. His overall research aim is to investigate how biochemical, microbiological, and clinical factors can help decision-making in the treatment of healthcare-associated infections, and he hopes to ultimately integrate these factors into robust risk-prediction algorithms for use by clinicians.
Diagnosis, Treatment, and Clinical Epidemiology of Clostridium difficile infection
Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C, Young VB, Aronoff DM, Malani PN. Poor Functional Status as a Risk Factor for Severe Clostridium difficile Infection in Hospitalized Older Adults. J Am Geriatr Soc. 2013;61(10):1738-42. PMCID: 3801297.
Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am J Gastroenterol. 2014;109(7):1065-71. DOI: 10.1038/ajg.2014.133.
Bagdasarian N, Rao K, Malani PN. Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review. JAMA. 2015;313(4):398-408.
Martinson J, Broadaway S, Lohman E, Johnson C, Alam MJ, Khaleduzzaman M, Garey KW, Schlackman J, Marsh JW, Young VB, Santhosh K, Rao K, Lyons RH, Walk ST. Evaluation of Portability and Cost of a Fluorescent PCR Ribotyping Protocol for Clostridium difficile Epidemiology. J Clin Microbiol. 2015; published online 28 January 2015.
Biomarkers and Predictive Modeling in Clostridium difficile infection
Rao K, Walk ST, Micic D, Chenoweth E, Deng L, Galecki AT, Jain R, Trivedi I, Yu M, Santhosh K, Ring C, Young VB, Huffnagle GB, Aronoff DM. Procalcitonin Levels Associate with Severity of Clostridium difficile Infection. PLoS One. 2013;8(3):e58265. PMCID: 3591407.
Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C, Young VB, Huffnagle GB, Aronoff DM. The Systemic Inflammatory Response to Clostridium difficile Infection. PLoS ONE. 2014;9(3):e92578. PMCID: 3958555
Islam J, Taylor AL, Rao K, Huffnagle G, Young VB, Rajkumar C, Cohen J, Papatheodorou P, Aronoff DM, Llewelyn MJ. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: A case–control study. Anaerobe. 2014;27(0):82-6. PMCID: 4140433.
Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, Santhosh K, Mogle JA, Galecki AT, LeBar W, Higgins P, Young VB, Aronoff DM. Clostridium difficile Ribotype 027: Relationship to Age, Detectability of Toxins A or B in Stool with Rapid Testing, Severe Infection, and Mortality. Clin Infect Dis. 2015; published online 31 March 2015.